All In Biotech

Drug Trial Radar · NCT03180840

Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks

Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™

Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

30

Actual

Start

Jul 10, 2017

Primary completion

Aug 1, 2020

Study completion Aug 1, 2020

Sponsor

Lead sponsor
ProtalixIndustry
Sponsor type
Industry
Collaborators
Chiesi Farmaceutici S.p.A.
First posted
Jun 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label switchover study will assess the safety, efficacy, and pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg administered every 4 weeks for 52 weeks in Fabry patients previously treated with ERT: agalsidase alfa or agalsidase beta for at least 3 years. Safety and efficacy exploratory endpoints will be evaluated throughout the study period and pharmacokinetics will be obtained on Day 1 and Week 52.

Conditions

  • Fabry Disease

Interventions

  • Pegunigalsidase alfaBiological

    Pegunigalsidase alfa 2 mg/kg every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse Events (TEAE) as Assessed by CTCAE v4.03Time frame: Month 12

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • UAB Medicine

    Birmingham, Alabama

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Infusion Associates

    Grand Rapids, Michigan

  • Institute of Metabolic Disease

    Dallas, Texas

  • University of Utah Hospital & Clinics

    Salt Lake City, Utah

  • O & O Alpan

    Fairfax, Virginia

  • UZ Antwerpen

    Edegem, Belgium

  • Fakultní poliklinika Všeobecné fakultní nemocnice v Praze

    Prague, Czechia

  • Rigshospitalet

    Copenhagen, Denmark

  • Azienda Ospedaliera Universitaria "Federico II"

    Naples, Italy

  • Helse Bergen HF Haukeland Universitetssykehus

    Bergen, Norway

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • The Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.